Who is BlueRock?
BlueRock Therapeutics, a wholly-owned and independently operated subsidiary of Bayer AG, is a leading engineered cell therapy company pioneering a new generation of cellular medicines. Leveraging our proprietary CELL+GENE™ platform, we direct cellular differentiation and genetically engineer cells to create transformative therapies for patients suffering from neurological and ophthalmological diseases.
Founded in 2016, BlueRock is at the forefront of the convergence of cell biology and genetic engineering. Our mission is to harness pluripotent stem cell technology and gene editing to deliver authentic, functional cell therapies that address the root causes of disease and offer hope to millions of patients worldwide.
Our Neurology Vision
BlueRock is advancing an innovative pipeline of cell therapies in neurology, focused on addressing the urgent needs of patients with neurodegenerative and neurological disorders. Our lead neurology program, bemdaneprocel (DA01), is a first-in-class, allogeneic cell therapy designed to replace lost dopaminergic neurons in patients with Parkinson’s disease. This program is currently in phase 3 development with the exPDite-2 clinical trial ongoing in the US, Canada, and Australia. Additional neurology pipeline assets, including DA02 and MG0X, are in research phase targeting other high-impact neurological conditions.
Our goal is to restore function, slow or halt disease progression, and transform the standard of care for patients with debilitating neurological diseases.
What Are We Doing?
Our foundational science enables the generation and directed differentiation of universal pluripotent stem cells into authentic, functional cells for allogeneic cellular therapies. We are passionate about realizing the promise of cell and gene therapy, shaping the future of regenerative medicine, and delivering new therapies to patients with limited or no treatment options.
About the Role
As BlueRock advances bemdaneprocel, DA02, MG0X, and other pipeline programs in neurology, we are seeking a visionary leader to join our team as Vice President, Head of Neurology Clinical Development. In this highly visible role, you will lead the clinical strategy and execution for our neurology cell therapy programs from IND-enabling studies through clinical development and regulatory submissions.
Reporting to the Chief Medical Officer, you will build and lead cross-functional teams, collaborate with internal and external partners, and play a pivotal role in shaping the future of cell therapy for neurological diseases. This position can be based in Cambridge, MA or New York City, NY, with remote or hybrid work arrangements available.